FDA Cites Manufacturing Issues for Cytisinicline - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA Cites Manufacturing Issues for Cytisinicline

Application supported by Phase 3 smoking-cessation data and long-term safety findings.

  • By

  • Kathryn Wighton

  • June 22, 2026

  • 3 min

Share

Objective:

To report on the FDA's Complete Response Letter regarding the New Drug Application for cytisinicline.

Approach:
    Key Findings:
    • The FDA identified no clinical efficacy or safety deficiencies in cytisinicline.
    • The Complete Response Letter was related to manufacturing compliance issues at a third-party facility.
    • Achieve Life Sciences plans to resubmit the New Drug Application reflecting new manufacturing processes.
    Interpretation:

    The FDA's feedback indicates a path forward for Achieve Life Sciences to address manufacturing concerns.

    Limitations:
    • The Complete Response Letter does not address clinical efficacy or safety, focusing solely on manufacturing issues.
    • The timeline for resubmission and potential approval is contingent on resolving manufacturing concerns.
    Conclusion:

    Achieve Life Sciences is working towards addressing FDA concerns and plans to resubmit its application for cytisinicline.

    Sources:

Original Source(s)

FDA Cites Manufacturing Issues for Cytisinicline

  • by Kathryn Wighton

  • June 22, 2026

Related Content

FDA monthly preview: Key September decisions to watch

Several FDA decisions across multiple specialties are expected this month.

Emergency diagnosis may flag poor outcomes beyond cancer

Across 13 noncancer conditions, emergency diagnosis was common and associated with higher 1-year mortality.

AI-Assisted MRI Method May Rival CT in Lung Nodule Detection

A rapid AI‐assisted imaging protocol detected nearly all clinically relevant solid lung nodules while closely matching CT for suspicious screening classifications.